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Using human papillomavirus (HPV) testing for cervical cancer screening in lower-resource settings (LRS) will result in a signifi-
cant number of screen-positive women. This analysis compares different triage strategies for detecting cervical precancer and
cancer among HPV-positive women in LRS. This was a population-based study of women aged 25–65 years living in China
(n57,541). Each woman provided a self-collected and two clinician-collected specimens. The self-collected and one clinician-
collected specimen were tested by two HPV DNA tests—careHPVTM and Hybrid Capture 2; the other clinician-collected speci-
men was tested for HPV16/18/45 E6 protein. CareHPVTM-positive specimens were tested for HPV16/18/45 DNA. HPV DNA-
positive women underwent visual inspection with acetic acid (VIA) and then colposcopic evaluation with biopsies. The perform-
ance for detection of cervical intraepithelial neoplasia grade 3 or cancer (CIN31) among HPV DNA-positive women was
assessed for different triage strategies: HPV16/18/45 E6 or DNA detection, VIA, colposcopic impression, or higher signal
strength (10 relative light units/positive control [rlu/pc]). The percent triage positive ranges were 14.8–17.4% for VIA,
17.8–20.9% for an abnormal colposcopic impression; 7.9–10.5% for HPV16/18/45 E6; 23.4–28.4% for HPV16/18/45 DNA;
and 48.0–62.6% for higher signal strength (10 rlu/pc), depending on the HPV test/specimen combination. The positivity for
all triage tests increased with severity of diagnosis. HPV16/18/45 DNA detection was approximately 70% sensitive and had
positive predictive values (PPV) of approximately 25% for CIN31. HPV16/18/45 E6 detection was approximately 50% sensitive
with a PPV of nearly 50% for CIN31. Different triage strategies for HPV DNA-positive women provide important tradeoffs in
colposcopy or treatment referral percentages and sensitivity for prevalent CIN31.
Cervical cancer incidence and mortality have declined signiﬁ-
cantly in those places that have effectively implemented
Papanicolaou (Pap) test-based screening.1 Yet cervical cancer
remains the second most common female cancer and third
most common cause of female cancer-related mortality glob-
ally, with an annual incidence of approximately 530,000 and
mortality of 275,000, respectively.2 This seeming contradic-
tion is explained by the fact that cervical cancer incidence
and mortality are approximately 10-fold greater in low- and
middle-income countries (LMIC), where Pap programs have
failed to be established because of the technical and ﬁnancial
barriers to implementation.1,3
Because of these limitations, alternative screening strat-
egies have been developed and evaluated, including molecular
testing for the necessary cause of cervical cancer, carcinogenic
human papillomavirus (HPV). DNA testing for HPV has
been shown to be more sensitive4–9 and more reliable10–12
than Pap testing. A key attribute of HPV testing related to its
high sensitivity is its excellent negative predictive value, pro-
viding near complete reassurance following a negative test
that the woman does not have cancer or precancer.13–15
Thus, a negative HPV DNA test does an excellent job of
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screening by ruling out disease in the primarily healthy pop-
ulation, permitting fewer screens of the general population in
lifetime. Affordable tests like careHPVTM (careHPVTM; QIA-
GEN, Gaithersburg, MD)16 and “tiered pricing” of higher
cost tests will make HPV testing increasingly more available
to LMIC. However, the challenge of using HPV testing, or
any screening test, is the management of screen-positive
women, as most women with a positive screening test (80%
to 90%) will not have concurrent disease (i.e., cervical pre-
cancer or cancer). This is an especially perplexing problem in
LMIC, where there are limited numbers of clinics, colposcop-
ists, pathologists and clinicians qualiﬁed to provide diagnosis
and treatment, and services must be prioritized for women at
highest risk for harboring precancer or cancer.17 In China,
ﬁndings showed a higher prevalence of HR-HPV infection
and CIN21, which suggests that the burden of cervical can-
cer in China especially in some rural areas is more substan-
tial than was previously reported with a much higher need
for comprehensive screening and will result in many more
HPV positive women to manage.18,19 Moreover, in the con-
text of a screen-and-treat program, where treatment is pro-
vided without colposcopy or biopsy, it may be desirable to
immediately treat only those at a higher risk of cervical pre-
cancer and cancer among the screen-positives to minimize
overtreatment.
In 2010, we launched a clinical study in 7,500 women living
in rural China as part of the Screening Technologies to
Advance Rapid Testing for Cervical Cancer Prevention—Util-
ity and Program Planning (START-UP) Project. The stated
goals of this study were to evaluate new strategies for screening
and management of screen positives that might be employed
in LMIC. Here, we report on our evaluation of different man-
agement or “triage” strategies for HPV DNA-positive women.
We explored both visual and molecular methods to distinguish
between HPV DNA-positive women at high and low risk of
cervical precancer and cancer. Further management of the lat-
ter might be deferred until there is evidence of increased risk
(e.g., HPV persistence),15,20,21 thereby increasing the
“predictive value” of the intervention and decreasing the use of
more invasive procedures and resources in lower-risk women.
Material and Methods
Population
The population for this study was recruited as follows: First,
we selected two high-risk communes from each county
(Yangcheng, Xinmi and Tonggu) according to the proposed
sample size. Second, the number of women aged 25–65
years in each commune was collected from the local
residence registry of the police ofﬁce. Third, we determined
the candidate villages for the study considering the size of
the village and the transportation conditions. Fourth, all the
women aged 25–65 years and living in the chosen villages
who had not undergone screening in the last ﬁve years were
invited to participate in the study if they met the study cri-
teria. The recruitment was stopped when the target sample
size was reached. We noted a challenge in the recruitment
of the oldest and youngest women as older women were
less willing to undergo screening and many of the younger
women were transient and could not be located. Thus, our
study population was biased toward women who were
35–50 years old.
Women aged 25–65 years were considered eligible if they
(i) had a cervix, (ii) had not been previously diagnosed with
cervical cancer, (iii) were not pregnant, (iv) were physically
able to undergo routine cervical cancer screening and (v)
were able to provide informed consent. We did not exclude
women if they had previous cervical cancer screening because
we assumed that even if a few women had been screened for
cervical cancer, the quality of cytology screening was likely to
be very poor. Women were excluded if they were not married
and reported never having had sexual intercourse. Local doc-
tors conducted the initial recruitment and eligibility screen-
ing. Eligibility was conﬁrmed at the study clinic. Eligible
women were then educated about the study and asked to
complete the written informed consent in order to participate
in the study.
Enrollment visit
Participants were given an education session about cervical
cancer prior to the start of the study procedures. First,
women were asked to complete a short risk-factor survey
administered by study personnel. Then, women were given
instructions on how to self-collect a vaginal sample and were
provided a private room to self-collect their vaginal specimen.
Next, women underwent a routine pelvic exam at which time
two cervical specimens were collected, the ﬁrst into a dry
tube for OncoE6TM Cervical Test (Arbor Vita Corporation)
testing and the second into dcm buffer (QIAGEN) for HPV
DNA testing. Then visual inspection with acetic acid (VIA)
was done and results were recorded.
What’s new?
The careHPVTM test is a novel technology for primary cervical cancer screening of women from lower-resource settings. How-
ever, triage strategies are needed to identify which HPV-positive women are at highest risk of cervical precancer and cancer.
Here, multiple viable and affordable strategies to manage HPV-positive women depending on local requirements and resources
are identified, based on evaluation of the performance of different triage strategies for developing countries. The different
strategies for women who test positive for HPV DNA provide important tradeoffs in colposcopy or treatment referral percen-
tages and sensitivity for cervical intraepithelial neoplasia grade 3 or cancer (CIN31).
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Clinical management
Women who tested positive for any of the six screening tests
performed (VIA, HPV E6 and HC2 and careHPVTM on
clinician-collected and self-collected specimens) were referred
to colposcopy and approximately 10% random sample of
women who tested negative for all screening tests (screen-nega-
tive women) underwent a second VIA and a rigorous colpo-
scopic evaluation that included using a microbiopsy protocol as
previously described.22 As dictated by the IRBs, women who
had no visible lesions had their screening result revealed and if
there were still no visible lesions, no biopsies were taken.
Laboratory tests
CareHPVTM was done as previously described16,23 at the clin-
ical sites by a laboratory technician who had a general level
of training comparable to the local hospital staff and who
was trained to run careHPVTM by a senior CICAMS techni-
cian. A research-use only pooled probe set targeting HPV16,
18 and 45 was developed for the study and ran on the same
careHPVTM platform with the same protocol on all
careHPVTM-positive specimens. The HPV DNA 16/18/45 test
was run periodically when there were sufﬁcient numbers to
nearly or completely ﬁll a batch of 90. A signal strength of
1.0 relative light units per positive control (rlu/pc) or greater
was considered positive for both tests.
HC2 was performed per the manufacturer’s instruction,
except that 50 mL of the dcm specimen was combined with
25 mL kit denaturation reagent rather than combining 1,000
mL of the STM specimen with 500 mL kit denaturation rea-
gent. Because HC2 cannot be set up at local clinical sites,
after careHPVTM testing, residual dcm specimens were sent
to the special lab on site and CICAMS’s technician per-
formed the HC2 test.
The Arbor Vita OncoE6TM Cervical Test is an immuno-
chromatographic test using a lateral ﬂow format; E6 oncopro-
teins of HPV types 16 and/or 18 and/or 45 (when present in
the sample solution) are captured by monoclonal antibodies
(mAb) immobilized on the porous membrane of the lateral
ﬂow strip, thus forming distinct test lines for E6 oncoproteins
of the respective HPV types. Detection of captured E6 onco-
proteins occurs via detector monoclonal antibodies recogniz-
ing epitopes on E6 distinct from those used for capture. The
detector mAbs are conjugated to alkaline phosphatase, allow-
ing for colorimetric visualization of a present capture mAb–
E6 oncoprotein–detector mAb sandwich upon development
with alkaline phosphatase substrate. Three test strips consti-
tute one test unit, with each test strip allowing for analysis of
one individual clinical specimen, and several units (of three
test strips each) can be used in parallel by one operator. The
time from sample collection to test results is typically around
2.5 hr. A control line is included on each strip and allows
veriﬁcation of detector reagent activity and proper sample
solution migration up the test strip.
OncoE6TM cervical testing was conducted as previously
described24 at the clinical site by local hospital personnel
supervised by CICAMS staff. Brieﬂy, a cervical specimen col-
lected using a polyester swab was stored in a tube without
buffer until tested. The swab specimen was treated in a two-
step process, ﬁrst with 933 mL of lysis solution and next with
87 mL of conditioning solution, both with 15-minute incuba-
tion under gentle agitation. Next, the specimen solution was
clariﬁed from insoluble components by centrifugation in a
table-top microcentrifuge for 10 minutes at >10,000 rpm. A
200-mL aliquot of the sample solution was then transferred
into a vial with lyophilized detector mAb; the test unit was
next inserted into the detector mAb vials, and the specimen
solutions ran up the test strips by capillary action. After 55
minutes, the test unit was transferred into vials with wash
solution, and after a 12-minute washing the test unit was
immersed into another set of vials containing developing
solution. After 15–25 minutes (depending on the ambient
temperature), the test unit was removed from the developing
solution vials and placed onto a reading guide, allowing for
visual inspection. Appearance of one or more test lines indi-
cated E6 oncoprotein of the corresponding HPV type present
in the initial cervical swab specimen.
Pathology
A CICAMS pathologist (Professor Xun Zhang) provided the
primary diagnosis of biopsies and surgical specimens, and the
worst of the two was used for the ﬁnal diagnosis in these
analyses. All initial biopsy diagnoses of CIN21 and a ran-
dom sample of <CIN2 were independently reviewed by an
expert US pathologist (MHS) to conﬁrm the results. There
was no qualitative difference in the results of this analysis
using either set of diagnoses (data not shown).
Analyses
We evaluated ﬁve different strategies to triage an HPV-
positive test by any of the four combinations of HPV tests
(careHPVTM or HC2) and specimen collection (clinician or
self): (i) colposcopic impression of low-grade disease or
worse, (ii) the second VIA conducted among the screen-
positive population referred to colposcopy, (iii) using a
higher cutpoint of 10.0 rlu/pc for the HPV DNA screening
test, (iv) the E6 test for HPV16/18/45 and (v) the HC2 DNA
test for HPV16/18/45 (among careHPVTM positives only).
We selected a cutpoint for colposcopy based on receiver-
operator curve analysis for the detection of CIN21 shown in
Supporting Information Figure 1; using metaplasia or worse
added little sensitivity and decreased speciﬁcity signiﬁcantly
while using a cutpoint of high-grade or worse was too insen-
sitive. We selected a DNA triage cutpoint of 10.0 rlu/pc
based on reports that the signal strength near the 1.0 rlu/pc
positive cutpoint were less predictive of CIN21 and CIN31,
and we wanted to evaluate HPV DNA test performance by
reducing the referral by approximately 50%.
We calculated the percent positive of each triage test
among any HPV-positive test result overall, by age groups
(<30, 30–39, 40–49 and 50 years and older) and by severity
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of histologic diagnosis. We calculated sensitivity, speciﬁcity,
positive and negative predictive values and odds ratio (OR)
for CIN21 and CIN31 for all triage tests among those
women who tested HPV DNA positive. A McNemar chi-
square test was used to assess differences in sensitivity and
speciﬁcity for CIN21 and CIN31 for paired-test results.
Results
We recruited 7,543 women aged 25–65 years from the three
clinical sites in China; 7,541 (99.9%) were of eligible age—
1,935 (25.7%) of whom had at least one positive HPV test
and were included in this analysis. The mean age, median
age and interquartile age range for this subpopulation (HPV-
positive women) were 46 years, 45 years and 39–53 years,
respectively. The percentages of test positive for clinician-
collected specimens tested by careHPVTM, self-collected
specimens tested by careHPVTM, clinician-collected speci-
mens tested by HC2 and self-collected specimens tested by
HC2 were 14.4%, 14.5%, 14.5% and 17.9%, respectively. For
HPV DNA detection, the four-way total agreement was
84.4% and the kappa was 0.669.
Among the HPV DNA positives by either specimen or
test, the percent positive for each triage test or method was
generally similar for all but using a 10.0 rlu/pc or higher cut-
point for the HPV DNA test (Table 1). The range of percent
positive for VIA was 14.8–17.4% and for colposcopic impres-
sion of low-grade or worse was 17.8–20.9%; HPV16/18/45 E6
detection was 7.9–10.5%, and HPV16/18/45 DNA (among
careHPVTM positives only) was 23.4–28.4%. By comparison,
using a 10 rlu/pc cutpoint for triage, the percent positive was
10% lower on self-collected specimens (48.0% for careHPVTM
and 52.1% for HC2) than using clinician-collected specimens
(58.3% for careHPVTM and 62.6% for HC2).
There were consistent patterns of percent positive for the
triage tests by age (Table 1): (i) both visual methods of tri-
age—colposcopy and VIA—decreased with age, (ii) both
HPV DNA methods of triage—the 10.0 rlu/pc cutpoint and
HPV16/18/45 detection—remained fairly constant with age
and (iii) E6 detection of HPV16/18/45 increased with
increasing age.
The percent positive for the triage tests among HPV
DNA-positive women increased with increasing severity of
diagnosis (Table 2). The percent positive for the 10 rlu/pc
cutpoint was generally higher for any diagnosis than the
other triage tests and was relatively constant for diagnoses of
CIN1 or more severe. As a consequence, the percent positive
(50%) for the 10 rlu/pc cutpoint among women with
<CIN2 was much greater than colposcopy (11%), VIA
(10%), DNA detection of HPV16/18/45 (20%), or E6
detection of HPV16/18/45 (5%). It is also noteworthy that
there was a large difference in the percent test positive
among the 10 rlu/pc cutpoint for CIN21 and CIN31
between the clinician- and self-collected specimens. Con-
versely, there was no appreciable difference in the percent
test positive for CIN21 and CIN31 for the other triage tests
between the different specimens.
The clinical performance of the triage tests among HPV
DNA-positive women for CIN21 is shown in Table 3 and
for CIN31 is shown in Table 4. The 10 rlu/pc cutpoint was
generally the most sensitive and least speciﬁc of triage tests
for both endpoints (p< 0.0001) except for the 10 rlu/pc cut-
point for self-collected specimens tested by careHPVTM.
DNA detection of HPV16/18/45 among careHPVTM positives
was generally the next most sensitive and the second least
speciﬁc. E6 detection of HPV16/18/45 was by far the most
speciﬁc for CIN21 (p< 0.0001 for all) and CIN31
(p 0.0001 for all), and its positive predictive value was
greater than 50% for CIN21 and almost 50% for CIN31.
For visual methods, colposcopy tended to be slightly more
sensitive and slightly less speciﬁc than VIA, although the dif-
ferences were not statistically signiﬁcant. For CIN21, the
sensitivity of colposcopy ranged from 55.3% to 55.8% and
the speciﬁcity ranged from 84.2% to 86.9%. On the other
hand, the sensitivity for VIA ranged between 46.0% and
46.8% and its speciﬁcity was between 86.1% and 88.6%. Simi-
lar results were observed for the CIN31 endpoint: the sensi-
tivity for colposcopy was between 63.3% and 63.9% and its
speciﬁcity was between 83.3% and 86.1%; the sensitivity for
VIA ranged from 52.6% to 54.2% and its speciﬁcity ranged
from 85.3% to 87.9%.
We also calculated the OR and 95% conﬁdence interval
(CI) as a summary measure of the association of positive tri-
age tests with the endpoints among HPV DNA-positive
women. E6 was the most strongly associated with CIN21
and CIN31. For example, E6 detection was strongly associ-
ated with CIN31 among women who tested careHPVTM-
positive on their clinician-collected specimen (OR: 17.9, 95%
CI: 11.1–28.9) and on their self-collected specimen (OR: 28.8,
95% CI: 17.0–48.8). The OR of 10 rlu/pc cutpoint (for
clinician-collected specimens only), VIA, colposcopy and
DNA for HPV16/18/45 were between 5 and 10 for CIN21
and between 5 and 15 for CIN31. At the other extreme, the
10 rlu/pc cutpoint for HC2 on self-collected specimens was
only weakly associated with CIN31 (OR: 2.3, 95% CI: 1.4–
3.6) and the 10 rlu/pc cutpoint for careHPVTM on self-
collected specimens was not associated with CIN31 (OR: 1.2,
95% CI: 0.8–1.9).
Discussion
We evaluated multiple strategies for managing HPV DNA-
positive women (triage) to expand the menu of options for
secondary cervical cancer prevention through screening,
management of screen positives, diagnosis and early treat-
ment of precancer and early cancer. More sensitive methods
of triaging HPV DNA-positive women to detect CIN31,
such as using a higher cutpoint or HPV16/18/45 DNA detec-
tion, were generally less speciﬁc, i.e., more false positives.
Conversely, highly speciﬁc methods for CIN31, such as
HPV16/18/45 E6, were less sensitive. In general, the relative
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performance of the different management strategies did not
depend on the method of screening to identify HPV-positive
women.
Appropriate screening strategies for LMICs differ from the
criteria for strategies appropriate for a high-income country.25
Screening programs, including the management strategies, will
need to be tailored to meet local needs in terms of ﬁnancial
and human resources, infrastructure and capacities, societal
norms and patient acceptability and level of cancer risk reduc-
tion desired. For instance, the Chinese government launched a
cervical cancer prevention program targeting 10 million rural
women using a Pap smear or VIA during the year of 2009–
2011.26 However, China lacks a sufﬁcient number of cyto-
pathologists or trained health care workers to screen an esti-
mated 500 million women in rural areas by Pap smear or
VIA. Objective, efﬁcient and high reproducible screening tests
are more desirable in China. The affordable HPV DNA test
(careHPVTM) has been developed for developing countries.16
Testing with careHPVTM at ﬁve-year intervals was reported to
be the optimal cervical cancer screening strategy for China
and has the best cost-effectiveness performance and the high-
est beneﬁt-cost ratio with moderate life outcomes in a model-
ing study.27 The decision to triage and by what method will
depend greatly on the weighting of the beneﬁts (e.g., cancer
prevention), the harms (e.g., false positive results leading to
unnecessary colposcopy, biopsy and possibly treatment) and
programmatic issues (e.g., losses to follow-up and availability
of health services) in the local context.
HPV DNA testing is uniquely suited as a screening test
because of its ability to “rule out” disease (i.e., women who
test negative for the necessary causal factor, HPV, are on
average many years away from developing invasive cervical
cancer).28 One of the challenges to widespread implementa-
tion of HPV DNA testing is its lower speciﬁcity. Some coun-
tries may have insufﬁcient capacity to act (e.g., colposcopy or
immediate treatment) on a HPV DNA-positive result. In
such places, strategies to prioritize women into higher-risk
groups in need of immediate intervention and lower-risk
groups who might be deferred for a period of time (e.g., 6–24
months) and then re-evaluated would be valuable.
Here we presented a variety of methods/tests that might
be employed to make the distinction between higher- and
lower-risk HPV DNA-positive women. Each method has dis-
tinct advantage(s) in terms of its performance and/or applic-
ability. Simply using a higher cutpoint of 10 rlu/pc as the
triage, with 10 rlu/pc for immediate intervention and 1.0–
9.9 rlu/pc deferred to follow-up, could be seen perhaps as the
easiest to implement because it requires no additional tests, if
the rlu/pc value was made available. Previous ﬁndings of pri-
mary screening strategies showed that the performance of
HPV DNA testing with an increased cutoff-point of 10 rlu/
pc may be ideal for a population such as China that could
utilize a single test primary screening strategy to allow for
infrequent screening and minimal infrastructure require-
ments.25,29 In this study using a cutpoint of 10 rlu/pc as the
triage was the most sensitive and least speciﬁc triage for
CIN21 and CIN31 when using a clinician-collected speci-
men but was much less effective when using a self-collected
specimen, such that it was no better than chance when tested
with careHPVTM.
Detection of HPV16/18/45 using a research-use only assay
on the careHPVTM platform was very sensitive, identifying
nearly 70% of all CIN21 and nearly 80% of all CIN31, and
had positive predictive value (PPV) around 25%, as predicted
by the etiologic fraction of cervical cancer and precancer
caused by these three HPV genotypes.30,31 Our ﬁndings are
consistent with data reported for a recently US Food and
Drug Administration-approved HPV DNA test that includes
HPV16 and HPV18 detection and previous reports from epi-
demiologic studies of the clinical utility of HPV16 or HPV16
and 18 detection.14,15,32 Newly developed US screening guide-
lines have reafﬁrmed the use of HPV16 or HPV16 and
HPV18 detection for management of HPV-positive, Pap-neg-
ative women.33 Since HPV16/18/45 DNA testing was done
reﬂexively from a careHPVTM-positive specimen, there was
no additional specimen or visit required, making it relatively
simple to implement. One caveat is that in order to maximize
its cost-effectiveness, HPV16/18/45 DNA testing on this plat-
form would need to be done in batches, which could take
several days to accumulate enough specimens and may pre-
clude same-day “screen-and-intervene” programs in clinics
with smaller numbers of women or a low HPV prevalence.
Visual methods of triage, such as colposcopy and VIA,
had lower sensitivity and better speciﬁcity for CIN21 and
CIN31 than DNA methods of triage. Colposcopy was more
sensitive but less speciﬁc than VIA. These methods could be
done on the same day or with a subsequent visit and fol-
lowed by the appropriate intervention (diagnosis and/or
treatment). Not surprisingly, visual methods have been pro-
posed as the triage method for HPV DNA testing in low-
resource settings, especially since VIA is already being used
in many countries. A review of the criteria used for VIA or
colposcopy could be required when working with women
known to be infected with carcinogenic HPV types.
We noted that the VIA performance was less sensitive but
more speciﬁc in this setting than reported in recent meta-
analyses/systematic reviews.34,35 We also observed that colpo-
scopy missed approximately 35% of disease (i.e., 35% of dis-
ease was found by random biopsies after negative colposcopic
assessment). Given the possible bias of using colposcopy to
assess VIA performance,36 we suggest that in order to accu-
rately assess the true performance of VIA, random biopsies
are required to identify lesions not visually apparent.
The detection of HPV16/18/45 E6 had sensitivity compa-
rable to VIA but had the best speciﬁcity of any triage test or
method and predicted that one out of every two HPV16/18/
45 E6 positives had clinically important disease (CIN31).
Thus, in the programmatic context in which referral to col-
poscopy or overtreatment in the context of a screen-and-treat
program needed to be minimized, detection of HPV16/18/45
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E6 by OncoE6TM Cervical Test might be one option to con-
sider. One caveat is that OncoE6TM Cervical Test only targets
HPV16, 18 or 45; targeting additional types is expected to
increase sensitivity without signiﬁcant impact on speciﬁcity,
since E6 overexpression is expected to be a characteristic of
precancer of any type rather than infection. Another limita-
tion is that a second dedicated sample was needed for testing,
so either co-collection of a clinician specimen for OncoE6TM
Cervical Testing or a second visit of the HPV DNA-positive
women would be required. Adapting the OncoE6TM Cervical
Test for use with specimens stored in buffers/transport
medium employed for HPV DNA testing would increase its
usability as a triage method.
As noted above, the sensitivity of the 10 rlu/pc cutoff for
triage dropped signiﬁcantly with the use of the self-collected
specimen compared to the clinician-collected specimen. The
consequence of this is that the 10 rlu/pc cutoff is a signiﬁcantly
more sensitive triage method using the clinician-collected speci-
men (p< 0.0001 for CIN31) but less sensitive using the self-
collected specimen (p5 0.0003 for CIN31) compared to
HPV16/18/45 DNA detection. A comparison of signal strength
(rlu/pc) and HPV16/18/45 detection (Supporting Information
Table 1) shows that low signal strength (12<10 rlu/pc),
HPV16/18/45 DNA-positive results from the clinician-collected
specimens identiﬁed fewer cases of CIN21 and CIN31 than
high signal strength (10 rlu/pc), HPV16/18/45 DNA-negative
results but the converse was true for self-collected specimens.
We acknowledge the following limitations in our study.
First, we did not conduct cytology, which is one of the stand-
ard methods being considered for triage of HPV positives in
higher-resource countries. Collection of a third cervical speci-
men (fourth specimen overall) would have been necessary to
include cytology in the study and we could not be sure of the
quality of the last specimen. The strengths and weaknesses of
cytologic methods have been well documented and described,
and therefore we felt justiﬁed in not studying it again. Sec-
ond, everyone who was HPV DNA positive went immedi-
ately to colposcopy, and therefore we did not evaluate the
triage tests/methods as they would actually be used in clinical
practice, with a negative triage deferred from evaluation until
a follow-up visit (e.g., one year). The consequence of this
design is that some CIN2 that might have otherwise
regressed37,38 in the triage-negative group was detected and
treated immediately and a small number of CIN3 could have
developed into invasive cancer during the time interval.
Our ﬁndings show that increasing the evidence and
knowledge about these programmatic choices will enable
countries, speciﬁcally LMICs, to make an informed decision
about what strategies might work best for screening their
women. The next step forward is large, realistic demonstra-
tions to show how assembling these different components
into a cogent program can perform in the real world.
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